The revision of the list of High Cost Medicines for serious diseases that are pre-approved through the Electronic Pre-Authorization System (EPS) was decided by the National Organization for the Provision of Health Services (EOPYY).
The new list he made public includes 128 preparations, all expensive and also for chronic diseases. The EOPYY, in fact, clarifies that the new drugs or new indications that are added are the following:
AMVUTTRA (treatment of transthyretin-mediated hereditary amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy).
BRUKINSA (for Waldenström macroglobulinemia, borderline lymphoma, chronic lymphocytic leukemia, refractory or relapsed nodular lymphoma) and
VYVGART (for generalized myasthenia gravis).
At the same time, the indications examined by the Electronic Prescribing System for the JAKAVI preparation were updated (examined for all its indications except for graft-versus-host disease).
“It is clarified that, for all the indications of approved drugs on the positive list, for which no relevant Ministerial Decision has been issued to date for inclusion in the positive list of reimbursed drugs, in accordance with Article 251 of Law 4512/2018, as amended by Article 24 of Law 4633/2019, a pre-approval procedure is required for their compensation”, reports EOPYY.
The entire list of 128 preparations available here.
#expensive #medicines #reimbursed #EOPYY #list
